Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Diabetes

Free Subscription Articles published in Lancet Retrieve available abstracts of 68 articles: HTML format

Single Articles

December 2026
1. ARUNDEL C, Mandefield L, Fairhurst C, Gkekas A, et al
   The diabetic foot after SWHSI-2: healing is not one size fits all - Authors' reply.
   Lancet. 2026;406:2925-2926.
   PubMed    
   
   
   
2. VAS P, Chong P
   The diabetic foot after SWHSI-2: healing is not one size fits all.
   Lancet. 2026;406:2924-2925.
   PubMed    
   
   
   
3. CHOW EW, Chow E
   Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity.
   Lancet. 2026;406:2866-2868.
   PubMed    
   
   
   
4. MUSKIET MHA, Nardone M, Rensen PCN, Cherney DZI, et al
   Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
   Lancet. 2026;406:2980-2983.
   PubMed     Abstract available
   
   
   July 2026
5. KIRBY T
   Anette Ziegler: breaking through boundaries in type 1 diabetes.
   Lancet. 2026;408:205.
   PubMed    
   
   
   June 2026
6. KHUNTI K, Zaccardi F, Mehta R, Gregg EW, et al
   Epidemiology of cardiometabolic multiple long-term conditions.
   Lancet. 2026;407:2641-2654.
   PubMed     Abstract available
   
   
   
7. BAJAJ HS, Welch M, Shah P, Luna E, et al
   Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
   Lancet. 2026;407:2402-2413.
   PubMed     Abstract available
   
   
   
8. ORTIZ A, Fernandez-Fernandez B
   Finerenone: kidney protection beyond type 2 diabetes.
   Lancet. 2026;407:2348-2350.
   PubMed    
   
   
   
9. ARODA VR, Davies MJ, Maaske J, Millegard M, et al
   Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial.
   Lancet. 2026 Jun 8:S0140-6736(26)00802-0. doi: 10.1016/S0140-6736(26)00802.
   PubMed     Abstract available
   
   
   
10. WELCH M, Forst T, Jia W, Del Pino PO, et al
    Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
    Lancet. 2026 Jun 8:S0140-6736(26)00800-7. doi: 10.1016/S0140-6736(26)00800.
    PubMed     Abstract available
    
    
    
11. DAVIES MJ, Aroda VR, Rosenstock J, Capehorn M, et al
    Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial.
    Lancet. 2026 Jun 8:S0140-6736(26)00748-8. doi: 10.1016/S0140-6736(26)00748.
    PubMed     Abstract available
    
    
    
12. VAN RAALTE DH, Muskiet MHA
    Beyond insulin escalation: REIMAGINE 3 and advanced type 2 diabetes care.
    Lancet. 2026 Jun 7:S0140-6736(26)01074-3. doi: 10.1016/S0140-6736(26)01074.
    PubMed    
    
    
    
13. ROSENSTOCK J, Billings LK, Gajria R, Giorgino F, et al
    Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
    Lancet. 2026 Jun 7:S0140-6736(26)01022-6. doi: 10.1016/S0140-6736(26)01022.
    PubMed     Abstract available
    
    
    March 2026
14. KASUJJA FX, Aikaeli F, Garrib A, van Widenfelt E, et al
    Integrated community-based versus facility-based care for people with HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-COMM): an open-label, multicountry, cluster-randomised trial.
    Lancet. 2026;407:1084-1094.
    PubMed     Abstract available
    
    
    February 2026
15. ROSENSTOCK J, Yabe D, Cox D, Li J, et al
    Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.
    Lancet. 2026 Feb 26:S0140-6736(26)00202-3. doi: 10.1016/S0140-6736(26)00202.
    PubMed     Abstract available
    
    
    
16. BONACA MP, Nordanstig J, Ludvik B, Videmark A, et al
    Response to STRIDE: semaglutide in peripheral artery disease and type 2 diabetes - Authors' reply.
    Lancet. 2026;407:573-574.
    PubMed    
    
    
    
17. ALNIMA T, Smits MM
    Response to STRIDE: semaglutide in peripheral artery disease and type 2 diabetes.
    Lancet. 2026;407:573.
    PubMed    
    
    
    
18. GROARKE EM, Turturice B, Patel BA, Quinn KA, et al
    VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies.
    Lancet. 2026;407:637-648.
    PubMed     Abstract available
    
    
    January 2026
19. NAUCK MA, Tuttle KR, Tschop MH, Bluher M, et al
    Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.
    Lancet. 2026 Jan 14:S0140-6736(25)02105-1. doi: 10.1016/S0140-6736(25)02105.
    PubMed     Abstract available
    
    
    
20. ABIZAID A, Mehran R, Oliva A, Chamie D, et al
    Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial.
    Lancet. 2026 Jan 8:S0140-6736(25)02157-9. doi: 10.1016/S0140-6736(25)02157.
    PubMed     Abstract available
    
    
    November 2025
21. HORN DB, Ryan DH, Kis SG, Alves B, et al
    Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.
    Lancet. 2025 Nov 20:S0140-6736(25)02165-8. doi: 10.1016/S0140-6736(25)02165.
    PubMed     Abstract available
    
    
    
22. ROEP BO
    Personalised prevention therapy in type 1 diabetes.
    Lancet. 2025 Nov 11:S0140-6736(25)02005-7. doi: 10.1016/S0140-6736(25)02005.
    PubMed    
    
    
    
23. ZIEGLER AG, Achenbach P, Weiss A, Berner R, et al
    Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial.
    Lancet. 2025 Nov 11:S0140-6736(25)01726-X. doi: 10.1016/S0140-6736(25)01726.
    PubMed     Abstract available
    
    
    
24. HEERSPINK HJL, Cardona JF, Jolly S, Pergola PE, et al
    Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.
    Lancet. 2025 Nov 8:S0140-6736(25)02014-8. doi: 10.1016/S0140-6736(25)02014.
    PubMed     Abstract available
    
    
    September 2025
25. ZIEGLER AG, Cengiz E, Kay TWH
    The future of type 1 diabetes therapy.
    Lancet. 2025 Sep 19:S0140-6736(25)01438-2. doi: 10.1016/S0140-6736(25)01438.
    PubMed     Abstract available
    
    
    
26. ISGANAITIS E, Laffel LM
    Dual incretin agonist for paediatric type 2 diabetes: an eagerly awaited opportunity.
    Lancet. 2025 Sep 19:S0140-6736(25)01908-7. doi: 10.1016/S0140-6736(25)01908.
    PubMed    
    
    
    
27. SPEAKE C
    ATG as disease-modifying therapy for new-onset type 1 diabetes.
    Lancet. 2025 Sep 18:S0140-6736(25)01773-8. doi: 10.1016/S0140-6736(25)01773.
    PubMed    
    
    
    
28. MATHIEU C, Wych J, Hendriks AEJ, Van Ryckeghem L, et al
    Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.
    Lancet. 2025 Sep 18:S0140-6736(25)01674-5. doi: 10.1016/S0140-6736(25)01674.
    PubMed     Abstract available
    
    
    
29. HANNON TS, Chao LC, Barrientos-Perez M, Pamidipati KC, et al
    Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2025 Sep 17:S0140-6736(25)01774-X. doi: 10.1016/S0140-6736(25)01774.
    PubMed     Abstract available
    
    
    July 2025
30. ZHOU B, Gregg EW, Danaei G, Ezzati M, et al
    Worldwide trends in diabetes prevalence: the NCD-RisC study - Authors' reply.
    Lancet. 2025;406:133-134.
    PubMed    
    
    
    
31. LIPSCOMBE L, Dasgupta K, Shah B
    Worldwide trends in diabetes prevalence: the NCD-RisC study.
    Lancet. 2025;406:132-133.
    PubMed    
    
    
    
32. BOYKO EJ, Ong KL, Duncan BB
    Worldwide trends in diabetes prevalence: the NCD-RisC study.
    Lancet. 2025;406:131-132.
    PubMed    
    
    
    
33. RUSSELL-JONES D, Klonoff DC
    Use of once-weekly insulins for type 1 diabetes.
    Lancet. 2025;406:130.
    PubMed    
    
    
    
34. LOVE KM, Kinlaw AC, Brown SA
    Use of once-weekly insulins for type 1 diabetes - Author's reply.
    Lancet. 2025;406:130-131.
    PubMed    
    
    
    
35. GASIOREK A, Heydorn A, Gabery S, Hjerpsted JB, et al
    Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.
    Lancet. 2025;406:135-148.
    PubMed     Abstract available
    
    
    June 2025
36. MISRA S, Khunti K, Goyal A, Gable D, et al
    Managing early-onset type 2 diabetes in the individual and at the population level.
    Lancet. 2025 Jun 20:S0140-6736(25)01067-0. doi: 10.1016/S0140-6736(25)01067.
    PubMed     Abstract available
    
    
    
37. LIM LL, Jones S, Cikomola JC, Hivert MF, et al
    Understanding the drivers and consequences of early-onset type 2 diabetes.
    Lancet. 2025 Jun 20:S0140-6736(25)01012-8. doi: 10.1016/S0140-6736(25)01012.
    PubMed     Abstract available
    
    
    
38. LUK A, Wild SH, Jones S, Anjana RM, et al
    Early-onset type 2 diabetes: the next major diabetes transition.
    Lancet. 2025 Jun 20:S0140-6736(25)00830-X. doi: 10.1016/S0140-6736(25)00830.
    PubMed     Abstract available
    
    
    
39. THE LANCET
    Early-onset type 2 diabetes: no time for defeatism.
    Lancet. 2025 Jun 20:S0140-6736(25)01295-4. doi: 10.1016/S0140-6736(25)01295.
    PubMed    
    
    
    
40. BLEVINS T, Dahl D, Perez Manghi FC, Murthy S, et al
    Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial.
    Lancet. 2025 Jun 20:S0140-6736(25)01069-4. doi: 10.1016/S0140-6736(25)01069.
    PubMed     Abstract available
    
    
    
41. PHILIS-TSIMIKAS A, Bergenstal RM, Bailey TS, Jinnouchi H, et al
    Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial.
    Lancet. 2025 Jun 20:S0140-6736(25)01044-X. doi: 10.1016/S0140-6736(25)01044.
    PubMed     Abstract available
    
    
    
42. CHOW EW, Chow E
    Future of once-weekly insulins in type 2 diabetes: efficacy and safety.
    Lancet. 2025 Jun 20:S0140-6736(25)01098-0. doi: 10.1016/S0140-6736(25)01098.
    PubMed    
    
    
    May 2025
43. GARDOSI J, Ewington LJ, Booth K, Bick D, et al
    Induction of labour versus standard care to prevent shoulder dystocia in fetuses suspected to be large for gestational age in the UK (the Big Baby trial): a multicentre, open-label, randomised controlled trial.
    Lancet. 2025 May 1:S0140-6736(25)00162-X. doi: 10.1016/S0140-6736(25)00162.
    PubMed     Abstract available
    
    
    March 2025
44. BONACA MP, Catarig AM, Houlind K, Ludvik B, et al
    Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00509-4. doi: 10.1016/S0140-6736(25)00509.
    PubMed     Abstract available
    
    
    
45. DENNIS JM, Young KG, Cardoso P, Gudemann LM, et al
    A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study.
    Lancet. 2025;405:701-714.
    PubMed     Abstract available
    
    
    
46. SEIDU S, Ikhile D
    Personalised type 2 diabetes therapy in primary care.
    Lancet. 2025;405:672-674.
    PubMed    
    
    
    January 2025
47. ADLER AI, Coleman RL, Whiteley WN, Holman RR, et al
    The legacy effect of hyperglycaemia in type 2 diabetes - Authors' reply.
    Lancet. 2025;405:29.
    PubMed    
    
    
    
48. HOU R, Ren J
    The legacy effect of hyperglycaemia in type 2 diabetes.
    Lancet. 2025;405:28-29.
    PubMed    
    
    
    
49. PRATTICHIZZO F, Ceriello A
    The legacy effect of hyperglycaemia in type 2 diabetes.
    Lancet. 2025;405:28.
    PubMed    
    
    
    November 2024
50. 
    Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants.
    Lancet. 2024;404:2077-93.
    PubMed     Abstract available
    
    
    
51. GUARIGUATA L, Sobers N
    Rising diabetes, lagging treatment, and the need for better systems.
    Lancet. 2024 Nov 12:S0140-6736(24)02422-X. doi: 10.1016/S0140-6736(24)02422.
    PubMed    
    
    
    September 2024
52. LOVE KM, Brown SA
    The promise of once-weekly insulins for type 1 diabetes: update on progress.
    Lancet. 2024;404:1081-1083.
    PubMed    
    
    
    
53. BERGENSTAL RM, Weinstock RS, Mathieu C, Onishi Y, et al
    Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial.
    Lancet. 2024;404:1132-1142.
    PubMed     Abstract available
    
    
    August 2024
54. KOSIBOROD MN, Deanfield J, Pratley R, Borlaug BA, et al
    Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
    Lancet. 2024 Aug 29:S0140-6736(24)01643-X. doi: 10.1016/S0140-6736(24)01643.
    PubMed     Abstract available
    
    
    
55. DELLGREN JL, Persad G, Emanuel EJ
    International coverage of GLP-1 receptor agonists: a review and ethical analysis of discordant approaches.
    Lancet. 2024 Aug 16:S0140-6736(24)01356-4. doi: 10.1016/S0140-6736(24)01356.
    PubMed    
    
    
    
56. MARECEK R, Kissling S, Teso AD, Vuignier Y, et al
    Chronic metabolic acidosis in a patient with diabetes on maintenance haemodialysis: mind the anion gap.
    Lancet. 2024;404:570-571.
    PubMed    
    
    
    July 2024
57. RODRIGUEZ-GUTIERREZ R
    Legacy effect of intensive glycaemic control in type 2 diabetes-the UKPDS.
    Lancet. 2024;404:100-102.
    PubMed    
    
    
    
58. SIMMONS D, Gupta Y, Hernandez TL, Levitt N, et al
    Call to action for a life course approach.
    Lancet. 2024;404:193-214.
    PubMed     Abstract available
    
    
    June 2024
59. LIU J, Li Y, Ge J, Yan X, et al
    Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
    Lancet. 2024 Jun 27:S0140-6736(24)01028-6. doi: 10.1016/S0140-6736(24)01028.
    PubMed     Abstract available
    
    
    
60. STRASSBURGER MATZENBACHER L, Alessi J, Telo GH
    Diabetes management amidst floods in Brazil.
    Lancet. 2024 Jun 26:S0140-6736(24)01177-2. doi: 10.1016/S0140-6736(24)01177.
    PubMed    
    
    
    
61. SWEETING A, Hannah W, Backman H, Catalano P, et al
    Epidemiology and management of gestational diabetes.
    Lancet. 2024 Jun 18:S0140-6736(24)00825-0. doi: 10.1016/S0140-6736(24)00825.
    PubMed     Abstract available
    
    
    
62. HIVERT MF, Backman H, Benhalima K, Catalano P, et al
    Pathophysiology from preconception, during pregnancy, and beyond.
    Lancet. 2024 Jun 18:S0140-6736(24)00827-4. doi: 10.1016/S0140-6736(24)00827.
    PubMed     Abstract available
    
    
    May 2024
63. JAFFAR S
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa - Authors' reply.
    Lancet. 2024;403:2292.
    PubMed    
    
    
    
64. CAI S, Xu Z, Zhao Y, Zuhlke L, et al
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet. 2024;403:2291.
    PubMed    
    
    
    
65. HAVLIR D, Kamya MR, Petersen M
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet. 2024;403:2291-2292.
    PubMed    
    
    
    
66. ADLER AI, Coleman RL, Leal J, Whiteley WN, et al
    Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).
    Lancet. 2024 May 17:S0140-6736(24)00537-3. doi: 10.1016/S0140-6736(24)00537.
    PubMed     Abstract available
    
    
    March 2024
67. BROWN DM, Boyer DS, Do DV, Wykoff CC, et al
    Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
    Lancet. 2024 Mar 7:S0140-6736(23)02577-1. doi: 10.1016/S0140-6736(23)02577.
    PubMed     Abstract available
    
    
    
68. GABRIELLE PH, Creuzot-Garcher C
    Can high-dose aflibercept satisfy unmet treatment needs in diabetic macular oedema?
    Lancet. 2024 Mar 7:S0140-6736(23)02760-5. doi: 10.1016/S0140-6736(23)02760.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum